All compounds, sacubitril/valsartan, valsartan, and LBQ, were obtained from Novartis Pharma AG in the form of powder. For in vitro studies, LBQ/valsartan (acting as surrogate of sacubitril/valsartan), valsartan, and LBQ were dissolved in 100% DMSO as 10 mmol/L stock solutions and stored at −80°C before use. Then the compound stock solution was diluted in cell culture to a final concentration (10 μmol/L). Sacubitril is converted to LBQ in vivo, so in the in vitro experiments, LBQ replaced sacubitril. In all of the experiments, the effect of DMSO as a vehicle was tested. For the in vivo studies, sacubitril/valsartan and valsartan were prepared according to “Guidance to investigators for formulating and administering LCZ696‐ABA and valsartan to rats” (Novartis). Sacubitril/valsartan was formulated in water at a concentration required for administration (68 mg/kg body weight per oral). Valsartan was first dissolved in 1 N NaOH to generate a stock solution of 200 mg/mL. Then water was added to generate a solution at a concentration required for administration (31 mg/kg body weight per oral). pH was adjusted for both sacubitril/valsartan and valsartan to approximately equal to pH 8 to 9. The treatment with sacubitril/valsartan and valsartan was performed by administration of the compounds orally once per day. The treatment commenced 1 week after surgery to avoid interference with reparative scar formation and potential hemodynamic compromise and followed for 7 weeks. miR‐181a antagomir, miR‐181a mimic, and NC were injected intramyocardially in the peri‐infarct region at the time of LAD ligation. miR‐181a antagomir, miR‐181a mimic, and NC were purchased from ThermoFisher and dissolved in PBS (15.6 nmol/L per dose) according to the manufacturer's instruction.